JSAM
ORKA

J. Safra Asset Management’s Oruka Therapeutics ORKA Stock Holding History

J. Safra Asset Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7K Sell
218
-254
-54% -$16.9K ﹤0.01% 321
2026
Q1 		$23.2K Buy
472
+317
+205% +$11K ﹤0.01% 297
2025
Q4 		$4.7K Buy
155
+131
+546% +$3.65K ﹤0.01% 437
2025
Q3 		$462 Hold
24
– – ﹤0.01% 463
2025
Q2 		$269 Buy
+24
New +$250 ﹤0.01% 366

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

J. Safra Asset Management's ORKA Position: Q2 2026 in Review

J. Safra Asset Management reduced its Oruka Therapeutics (ORKA) stake by 54% in Q2 2026, selling an estimated $16.9K and leaving 218 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #321.

J. Safra Asset Management first reported a position in ORKA in Q2 2025 and has held it in 5 quarters since. The position peaked at $23.2K in Q1 2026. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • J. Safra Asset Management held 218 shares of Oruka Therapeutics worth $20.7K as of Q2 2026.
  • J. Safra Asset Management sold 254 Oruka Therapeutics shares in Q2 2026, an estimated $16.9K.
  • Oruka Therapeutics made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #321 holding.
  • J. Safra Asset Management first reported a position in Oruka Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • J. Safra Asset Management's Oruka Therapeutics position peaked at $23.2K in Q1 2026.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.